HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 901–1,000 of 1,008
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Ilyas, S. I., & Borad, M. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.12 · Cited by 49
“Cancer cells can subvert this essential regulatory function to facilitate malignant transformation (46).”
BackgroundHSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC
Han, J., Goldstein, L. A., Hou, W., Chatterjee, S., Burns, T. F., & Rabinowich, H. (2018) · Autophagy · doi:10.1080/15548627.2018.1434471 · Cited by 43
“functions in the conformational control of multiple client proteins involved in tumor cell development and growth.(1) Inhibi-”
BackgroundDecanalizing thinking on genetic canalization
Geiler‐Samerotte, K., Sartori, F. M. O., & Siegal, M. L. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.05.008 · Cited by 42
“[17,42,43], 2) allow organisms evolving under strong genetic drift to avoid death as a result of mutation accumulation [12], 3) promote evolvability by allowing cryptic genetic variation to accumulate in genomes [11,29], and 4) provide a selective advantage that encouraged the maintenance of chaperone systems over evo…”
BackgroundHyun, S. Y., Le, H. T., Nguyen, C.-T., Yong, Y.-S., Boo, H., Lee, H. J., Lee, J. S., Min, H.-Y., Ann, J., Chen, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32196-6 · Cited by 44
The Multifaceted Role of HSF1 in Tumorigenesis
Alasady, M. J., & Mendillo, M. L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-40204-4_5 · Cited by 42
“In support of this idea, there is an extensive body of research that demonstrates the importance of HSP90 in chaperoning mutated oncoproteins critical in carcinogenesis (Whitesell and Lindquist, 2005; Jaeger and Whitesell, 2018).”
BackgroundAn aquatic virus exploits the IL6-STAT3-HSP90 signaling axis to promote viral entry
Hou, G., Lv, Z., Liu, W., Xiong, S., Zhang, Q., Li, C., Wang, X., Hu, L., Ding, C., Song, R., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011320 · Cited by 45
Sun, J. L., Lin, C., Qin, X., Dong, X., Tu, Z., Tang, F., Chen, C., & Zhang, J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.009 · Cited by 41
Sulforaphane attenuates EGFR signaling in NSCLC cells
Chen, C., Yu, Z.-Y., Chuang, Y., Huang, R.-M., & Wang, T. V. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0139-x · Cited by 41
“Sulforaphane enhances the antitumor activity of 17-AAG in NSCLC cells in vitro and in vivo Heat shock protein 90 (HSP90) inhibitors reportedly have antitumor effects on TKI-resistant NSCLC cells harboring the T790M mutation in EGFR [24,25].”
BackgroundInfluentialSong, X., & Luo, Y. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.046 · Cited by 43
“Recently, Hsp90 was shown to be overexpressed in cancer cells, with several oncoproteins identified as its client proteins [3].”
BackgroundCell Surface Cdc37 Participates in Extracellular HSP90 Mediated Cancer Cell Invasion
Hamidieh, A. E., Grammatikakis, N., & Patsavoudi, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042722 · Cited by 40
“Over the past years there has been increasing evidence demonstrating that intracellular HSP90 plays a pivotal role in the acquisition and maintenance of the malignant phenotype [12,13,14,15].”
BackgroundGao, L., & Harhaj, E. W. (2013) · Journal of Virology · doi:10.1128/jvi.02006-13 · Cited by 39
Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment
Wen, P. Y., Kesari, S., & Drappatz, J. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.733 · Cited by 43
Design of Allosteric Stimulators of the Hsp90 ATPase as New Anticancer Leads
D’Annessa, I., Sattin, S., Tao, J., Pennati, M., Sànchez‐Martìn, C., Moroni, E., Rasola, A., Zaffaroni, N., Agard, D. A., Bernardi, A., et al. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201700169 · Cited by 40
Alexandrova, E. M., & Moll, U. M. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.145 · Cited by 40
Scaffolds and chaperones in myofibril assembly: putting the striations in striated muscle
Crawford, G. L., & Horowits, R. (2011) · Biophysical Reviews · doi:10.1007/s12551-011-0043-x · Cited by 39
“A key feature in the C-terminal domain of Hsp90 is the presence of a conserved motif that binds to tetratricopeptide repeats (TPR) present in many co-chaperones (Whitesell and Lindquist 2005).”
Karkoulis, P. K., Stravopodis, D. J., Konstantakou, E. G., & Voutsinas, G. E. (2013) · Cancer Cell International · doi:10.1186/1475-2867-13-11 · Cited by 39
“The Hsp90 chaperone complex maintains the correct conformational folding, functional integrity and proteolytic turnover of a broad range of protein clients that are implicated in various signal transduction pathways controlling, among others, cell survival and proliferation [2,4].”
BackgroundKurashina, R., Ohyashiki, J. H., Kobayashi, C., Hamamura, R., Zhang, Y., Hirano, T., & Ohyashiki, K. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.012 · Cited by 38
Liu, J., Wang, F., Ma, Z., Wang, X., & Wang, Y. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12020946 · Cited by 39
“Hsp90 consists of a highly conserved N-terminal domain, a charged linker, and a highly conserved C-terminal region, the charged linker is not important for Hsp90 function, and the inhibitors of Hsp90 mainly bind to the N-and C-terminal regions [16–18].”
BackgroundZhang, C., Wang, X., Liu, H., Zhang, M., Geng, M., Sun, L., Shen, A., & Zhang, A. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.043 · Cited by 39
Wang, X., Zhang, Y., Ponomareva, L. V., Qiu, Q., Woodcock, R. M., Elshahawi, S. I., Chen, X., Zhou, Z., Hatcher, B. E., Hower, J. C., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201612447 · Cited by 40
Stabilization of Notch1 by the Hsp90 Chaperone is Crucial for T-Cell Leukemogenesis
Wang, Z., Hu, Y., Xiao, D., Wang, J., Liu, C., Xu, Y., Shi, X., Jiang, P., Huang, L., Li, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2880 · Cited by 43
“This dependence on Hsp90 appears to be a vulnerability of cancer cells and has led to the development of drugs aimed at depleting the molecular chaperone and degrading cancer proteome, leading to loss of tumor cell viability (8).”
BackgroundSpiegelberg, D., Abramenkovs, A., Mortensen, A. C. L., Lundsten, S., Nestor, M., & Stenerlöw, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-62293-4 · Cited by 43
Banerjee, M., Hatial, I., Keegan, B. M., & Blagg, B. S. J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107747 · Cited by 43
Seclì, L., Avalle, L., Poggio, P., Fragale, G., Cannata, C., Conti, L., Iannucci, A., Carrà, G., Rubinetto, C., Miniscalco, B., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3150 · Cited by 39
“Indeed, cancer cells overexpress and are addicted to chaperone proteins (1, 2).”
BackgroundLiu, Z., Sang, X., Wang, M., Liu, Y., Liu, J., Wang, X., Liu, P., & Cheng, H.-L. M. (2021) · Oncogene · doi:10.1038/s41388-021-02015-w · Cited by 40
Li, Y., Zhang, T., Schwartz, S. J., & Sun, D. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.596645 · Cited by 42
“Inhibition of Hsp90 may result in simultaneous degradation of multiple oncogenic client proteins, such as kinases, hormone receptors, and transcription factors in cancers (15,16).”
BackgroundZagouri, F., Sergentanis, T. Ν., Nonni, A., PAPADIMITRIOU, C. A., Michalopoulos, N. V., Domeyer, P.-R. J., Theodoropoulos, G. E., Lazaris, A. C., Patsouris, E., Zogafos, E., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-353 · Cited by 39
“Nevertheless, the steady numerical increase in Hsp90 Allred score along the ductal continuum may point to a simultaneous underlying increase in cellular stress, as well as to the multifaceted role mediated by Hsp90 in regulating the stability and function of many oncogenic and anti-oncogenic proteins, such as (ER), p5…”
BackgroundKim, Y. J., Lee, S. A., Myung, S. C., Kim, W., & Lee, C. S. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0997-9 · Cited by 39
“They promote tumor cell survival, growth, and metastasis by allowing continued protein translation and cellular proliferation [7].”
BackgroundKawabe, M., Mandić, M., Taylor, J. L., Vasquez, C. A., Wesa, A. K., Neckers, L. Μ., & Storkus, W. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4511 · Cited by 42
“Interestingly, many receptor tyrosine kinase serve as client proteins for the molecular chaperone heat shock protein 90 (HSP90),(5) a protein designed to stabilize and refold denatured proteins into their native conformations to preserve their function and utility in normal and stressed cells (23).”
Wu, D.-W., Chen, T.-C., Huang, H., & Lee, H. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.192 · Cited by 39
Exploring Erythrocytes as Blood Biomarkers for Alzheimer’s Disease
Stevenson, A. J., Lopez, D., Khoo, P. L. Z., Kalaria, R. N., & Mukaetova-Ladinska, E. B. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170363 · Cited by 40
“It has a diverse function in cellular-signaling pathways and cellular development, currently extensively researched in preventing cancer proliferation [72].”
BackgroundRobles, A. I., Wright, M. H., Gandhi, B., Feis, S. S., Hanigan, C. L., Wiestner, A. U., & Varticovski, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1178 · Cited by 40
Maddalena, F., Condelli, V., Matassa, D. S., Pacelli, C., Scrima, R., Lettini, G., Li Bergolis, V., Pietrafesa, M., Crispo, F., Piscazzi, A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12814 · Cited by 38
Cryo-EM structures reveal a multistep mechanism of Hsp90 activation by co-chaperone Aha1
Liu, Y., Sun, M., Myasnikov, A. G., Elnatan, D., Delaeter, N., Nguyenquang, M., & Agard, D. A. (2020) · doi:10.1101/2020.06.30.180695 · Cited by 37
Calderwood, S. K. (2013) · PubMed · Cited by 43
Jung, M. K., Park, Y., Song, S. B., Cheon, S. Y., Park, S., Houh, Y., Ha, S., Kim, H. J., Park, J. M., Kim, T. S., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.170 · Cited by 38
“HSP90 is found in numerous cancer cells including melanoma cells, and its expression is positively correlated with metastatic potential (Becker et al., 2004; Whitesell and Lindquist, 2005; McCarthy et al., 2008).”
BackgroundHeat shock protein 90 regulates stabilization rather than activation of soluble guanylate cyclase
Nedvetsky, P. I., Meurer, S., Opitz, N., Nedvetskaya, T. Y., Müller, H., & Schmidt, H. H. H. W. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.12.025 · Cited by 38
“Hsp90 is a molecular chaperone participating in many cellular signal transduction and gene expression pathways [21–23].”
BackgroundAneuploidy and proteotoxic stress in cancer
Donnelly, N., & Štorchová, Z. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.976491 · Cited by 38
“Proteotoxic stress and constitutive activation of the heat shock factor protein 1 (HSF1)-regulated heat shock response (HSR) pathway are among the recurring features of malignant cells, and inhibition of molecular chaperones represents a promising therapeutic strategy for cancer treatment.(3) It has been proposed that…”
BackgroundSun, H.-P., Jia, J., Jiang, F., Xu, X., Liu, F., Guo, X., Cherfaoui, B., Huang, H., Pan, Y., & You, Q. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.061 · Cited by 40
Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor
Vassallo, A., Vaccaro, M. C., Tommasi, N. D., Piaz, F. D., & Leone, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074266 · Cited by 38
“survival, and include kinases, nuclear hormone receptors, transcription factors and other proteins associated with almost all the hallmarks of cancer [4,5].”
Eckl, J. M., Scherr, M. J., Freiburger, L. A., Daake, M., Sattler, M., & Richter, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.693150 · Cited by 42
“Given the recent evolution of Hsp90 as a potential cancer target (21-23), it is important to clarify the mechanism and role of the chaperone-kinase interaction.”
BackgroundResults from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
Shah, S. J., Luke, J. J., Jacene, H. A., Chen, T., Giobbie‐Hurder, A., Ibrahim, N., Buchbinder, E. L., McDermott, D. F., Flaherty, K. T., Sullivan, R. J., et al. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000509 · Cited by 38
Alcohol Modulates the Biogenesis and Composition of Microglia-Derived Exosomes
Crenshaw, B. J., Kumar, S., Bell, C. R., Jones, L. B., Williams, S. D., Saldanha, S. N., Joshi, S., Sahu, R., Sims, B., & Matthews, Q. L. (2019) · Biology · doi:10.3390/biology8020025 · Cited by 38
Zhu, L., Retana, D., García‐Gómez, P., Álvaro‐Espinosa, L., Priego, N., Masmudi‐Martín, M., Yebra, N., Miarka, L., Hernández-Encinas, E., Blanco‐Aparicio, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114552 · Cited by 43
“…only to maintain numerous pro-survival oncoproteins and transcription factors, but also to buffer proteotoxic stress induced during oncogenic transformation and progression (Whitesell & Lindquist, 2005) as well as to regulate mechanisms of immune evasion (Fionda et al, 2009; Kawabe et al, 2009).”
BackgroundMohammed, O. A., Abdel‐Reheim, M. A., Saleh, L. A., Alamri, M. M. S., Alfaifi, J. A., Adam, M. I. E., Farrag, A. A. M., AlQahtani, A. A. J., BinAfif, W. F., Hashish, A. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081123 · Cited by 38
Physiological Adaptations of Stressed Fish to Polluted Environments: Role of Heat Shock Proteins
Padmini, E. (2010) · Reviews of Environmental Contamination and Toxicology · doi:10.1007/978-1-4419-6260-7_1 · Cited by 45
Role of Heat Shock Proteins in Viral Infection
Santoro, M., Amici, C., & Rossi, A. (2009) · Heat shock proteins · doi:10.1007/978-90-481-2976-8_3 · Cited by 38
“Hsp90 is an abundant molecular chaperone which binds to a specific set of client proteins, including intracellular receptors and signal transduction proteins, facilitating their folding and stability [141].”
BackgroundKim, W.-C., Lee, J. S., Lee, D., Cai, X. F., Shin, J. C., Lee, K., Lee, C., Ryu, S., Paik, S., Lee, J. J., et al. (2007) · ChemBioChem · doi:10.1002/cbic.200700196 · Cited by 38
Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel HSP90 inhibitors
Xiang, Y., Qian, C.-W., Xing, G., Hao, J., Xia, M., & Wang, Y. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.079 · Cited by 38
Ro, J. Y. (2011) · Oncology Letters · doi:10.3892/ol.2011.522 · Cited by 41
“Heat shock protein 90 (HSP90) is a molecular chaperone required for the stability and function of various client proteins, which mediate a major property necessary for the transformation of a normal cell to a cancer cell (6,7).”
Casale, E., Amboldi, N., Brasca, M. G., Caronni, D., Colombo, N., Dalvit, C., Felder, E. R., Fogliatto, G., Galvani, A. P., Isacchi, A., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.056 · Cited by 40
The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases
Lehner, F., Kulik, U., Klempnauer, J., & Borlak, J. T. (2007) · The FASEB Journal · doi:10.1096/fj.06-6575com · Cited by 38
“Indeed, induction of proteosomal degradation of HSP90 superchaperone complexes is clinically perused to abrogate oncogenic protein expression ( 19 ).”
BackgroundKushchayeva, Y. S., Jensen, K. E., Recupero, A., Costello, J., Patel, A. D., Kłubo-Gwieździńska, J., Boyle, L., Burman, K. D., & Vasko, V. V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3369 · Cited by 38
Molecular Clock: An Anti-neo-Darwinian Legacy
Takahata, N. (2007) · Genetics · doi:10.1534/genetics.104.75135 · Cited by 42
“It can store hidden phenotypic variation and its change can produce a profusion of morphological changes, for instance, by affecting interaction with various proteins in signal-transduction pathways or by inducing epigenetic alterations in gene expression (Whitesell and Lindquist 2005).”
BackgroundBanerji, U., Sain, N., Sharp, S. Y., Valenti, M. R., Asad, Y. J., Ruddle, R. R., Raynaud, F. I., Walton, M. I., Eccles, S. A., Judson, I. R., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0662-x · Cited by 40
“In normal cells it plays an important role in the stress response and buffering genetic mutations at the protein level [6, 27, 31, 61].”
BackgroundHeat shock proteins in animal neoplasms and human tumours—a comparison
Romanucci, M., Bastow, T., & della Salda, L. (2008) · Cell stress & chaperones (Print) · doi:10.1007/s12192-008-0030-8 · Cited by 33
“that would otherwise be lethal (Whitesell and Lindquist 2005).”
Spreafico, A., Delord, J., Mattos‐Arruda, L. D., Bergé, Y., Rodon, J. A., Cottura, E., Bedard, P. L., Akimov, M., Lu, H. L., Pain, S., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.653 · Cited by 37
“Overexpression of HSPs, in particular HSP90, with consequent oncogenic protein stabilisation, stimulation of cell proliferation, survival and angiogenesis has been shown to occur commonly in cancer cells (Whitesell and Lindquist, 2005; Powers and Workman, 2007; Neckers and Workman, 2012).”
BackgroundIschia, J. J., Fred Saad, C., & Gleave, M. E. (2013) · Current Opinion in Urology · doi:10.1097/mou.0b013e32835e9f1a · Cited by 37
“Hsp90 is an ATPase-dependent molecular chaperone required for protein folding, maturation and conformational stabilization of many client proteins including growth factor receptors, cell cycle regulators and signaling kinases, such as Akt, ERK, Her-2 and Raf-1 [17].”
BackgroundSynthesis and antiviral activity of some novel indole-2-carboxylate derivatives
Xue, S.-T., Ma, L., Gao, R., Li, Y., & Li, Z. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.06.003 · Cited by 37
Mohebati, A., Guttenplan, J. B., Kochhar, A., Zhao, Z., Kosinska, W., Subbaramaiah, K., & Dannenberg, A. J. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0002 · Cited by 37
“Inhibitors of Hsp90 suppress levels of numerous client proteins and are being evaluated as potential anticancer agents [46, 48, 49].”
RetractedPaul, D., Chanukuppa, V., Reddy, P. J., Taunk, K., Adhav, R., Srivastava, S., Santra, M. K., & Rapole, S. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.02.008 · Cited by 37
“Further,many studies have highlighted that HSP90 levels were elevated in cancer cells and considered as one of the good cancer target [17].”
BackgroundDing, G., Chen, P., Zhang, H., Huang, X., Zang, Y., Li, J., Li, J., & Wong, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.727214 · Cited by 38
“HSP90 (90-kDa heat-shock protein) is one of the most abundant and conserved molecular chaperone essential in eukaryotic cells (19).”
BackgroundSecreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity
Nolan, K. D., Kaur, J., & Isaacs, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.14252 · Cited by 38
“Heat-shock protein 90 (Hsp90), a highly conserved molecular chaperone, is frequently upregulated in tumors [23], and has been an attractive molecular target for pharmacological intervention [24].”
BackgroundAriyasu, S., Mu, J., Zhang, X., Huang, Y., Yeow, E. K. L., Zhang, H., & Xing, B. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00741 · Cited by 37
Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain
Terracciano, S., Russo, A., Chini, M. G., Vaccaro, M. C., Potenza, M., Vassallo, A., Riccio, R., Bifulco, G., & Bruno, I. (2018) · Scientific Reports · doi:10.1038/s41598-017-14902-y · Cited by 37
Modulation of protein fate decision by small molecules: targeting molecular chaperone machinery
Wang, L., Xu, X., Jiang, Z., & You, Q. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.018 · Cited by 40
CKS1B as Drug Resistance-Inducing Gene—A Potential Target to Improve Cancer Therapy
Shi, W., Huang, Q., Xie, J., Wang, H., Yu, X., & Zhou, Y. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.582451 · Cited by 37
“Overexpression of Hsp90 has been observed in many cancer types, and it is speculated that abnormal Hsp90 signaling must be maintained for the survival of malignant cells (42).”
BackgroundHuang, T.-Y., Chen, S., Han, H., Li, H., Huang, Z., Zhang, J., Yin, Q., Wang, X., Ma, X., Dai, P., et al. (2014) · Europe PMC (PubMed Central) · Cited by 37
Isoxazolo(aza)naphthoquinones: A new class of cytotoxic Hsp90 inhibitors
Bargiotti, A., Musso, L., Dallavalle, S., Merlini, L., Gallo, G., Ciacci, A., Giannini, G., Cabri, W., Penco, S., Vesci, L., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.03.036 · Cited by 37
Kim, S. H., Kang, J. G., Kim, C. S., Ihm, S., Choi, M. G., Yoo, H. J., & Lee, S. J. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.060 · Cited by 37
Li, B., You, J., Chen, L., Zhang, J., Zhang, N., Li, H., Huang, T., Kong, X., & Cai, Y. (2013) · BioMed Research International · doi:10.1155/2013/267375 · Cited by 44
Heat Shock Proteins in the Human Eye
Urbak, L., & Vorum, H. (2010) · International Journal of Proteomics · doi:10.1155/2010/479571 · Cited by 37
“Just as for retinoblastoma and uveal melanoma, Hsps have been found to be overexpressed in various other cancers in comparison to normal tissue suggesting that the increased chaperone expression contributes to oncogenesis at several levels [78].”
BackgroundBlockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer
Sachdev, J. C., & Jahanzeb, M. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.07.001 · Cited by 41
In Vitro Anticancer Effect of Gedunin on Human Teratocarcinomal (NTERA-2) Cancer Stem-Like Cells
Tharmarajah, L., Samarakoon, S. R., Ediriweera, M. K., Piyathilaka, P., Tennekoon, K. H., Senathilake, K. S., Rajagopalan, U., Galhena, P., & Thabrew, I. (2017) · BioMed Research International · doi:10.1155/2017/2413197 · Cited by 38
Discovery of Small-Molecule Inhibitors of the HSP90-Calcineurin-NFAT Pathway against Glioblastoma
Liu, Z., Li, H., He, L., Xiang, Y., Tian, C., Li, C., Tan, P., Ji, J., Tian, Y., Du, L., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2018.11.009 · Cited by 37
“pathways (Mahalingam et al., 2009; Whitesell and Lindquist, 2005), our study unveils the importance of a previously neglected pathway that involves calcineurin and NFAT.”
BackgroundPimitespib for the Treatment of Advanced Gastrointestinal Stromal tumors and Other Tumors
Doi, T., Yamamoto, N., & Ohkubo, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1172 · Cited by 36
Novel agents and new therapeutic approaches for treatment of multiple myeloma
Ria, R., Reale, A., & Vacca, A. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i2.73 · Cited by 40
N-Aryl-benzimidazolones as novel small molecule HSP90 inhibitors
Bruncko, M., Tahir, S. K., Song, X., Chen, J., Ding, H., Huth, J. R., Jin, S. S., Judge, R. A., Madar, D. J., Park, C. H., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.10.010 · Cited by 39
Singh, U., Bongcam‐Rudloff, E., & Westermark, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005050 · Cited by 36
“Unlike normal cells, tumor cells have higher proteotoxic stress and require higher levels of chaperones to survive [23].”
BackgroundMurata, T., Iwata, S., Siddiquey, M. N. A., Kanazawa, T., Goshima, F., Kawashima, D., Kimura, H., & Tsurumi, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063566 · Cited by 36
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
Shi, H., Zhang, W., Zhi, Q., & Jiang, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5467-2 · Cited by 38
“HSP machinery, especially the novel pro-survival and antiapoptotic system of HSP90, is highly up-regulated and activated in cancer cells [218].”
BackgroundDysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion
Armstrong, H., Gillis, J. L., Johnson, I. R. D., Nassar, Z. D., Moldovan, M. V., Levrier, C., Sadowski, M. C., Chin, M. Y., Guns, E. S. T., Tarulli, G. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19871-4 · Cited by 39
The structure-function relationship of oncogenic LMTK3
Ditsiou, A., Cilibrasi, C., Simigdala, N., Papakyriakou, A., Milton‐Harris, L., Vella, V., Nettleship, J. E., Lo, J. H., Soni, S., Smbatyan, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc3099 · Cited by 36
“HSP90 is a well-characterized molecular chaperone that plays an essential role in the folding and stability of a host of cellular proteins, notably including a large subset of eukaryotic protein kinases (51, 52).”
Chen, L., Fujisawa, N., Takanohashi, M., Najmina, M., Uto, K., & Ebara, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052542 · Cited by 36
The penalty of stress ‐ Epichaperomes negatively reshaping the brain in neurodegenerative disorders
Ginsberg, S. D., Joshi, S., Sharma, S., Guzman, G., Wang, T., Arancio, O., & Chiosis, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15525 · Cited by 41
“…or several oncoproteins, termed “client protein(s),” required HSP90 for structural stabilization and/or functional modulation, then an HSP90 inhibitor could facilitate the degradation of such client(s) in tumors, and in turn the tumor will respond to HSP90 therapy (Whitesell & Lindquist, 2005).”
BackgroundHsp90 is involved in the formation of P-bodies and stress granules
Matsumoto, K., Minami, M., Shinozaki, F., Suzuki, Y., Abe, K., Zenno, S., Matsumoto, S., & Minami, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.088 · Cited by 40
Mohindra, V., Tripathi, R. K., Yadav, P., Singh, R. K., & LAL, K. K. (2015) · Molecular Biology Reports · doi:10.1007/s11033-015-3855-0 · Cited by 36
Sanghvi, M., Moaddel, R., & Wainer, I. W. (2011) · Journal of Chromatography A · doi:10.1016/j.chroma.2011.05.067 · Cited by 36
Conejo-Garcia, J. R., Barluenga, S., Beebe, K. E., Neckers, L., & Winssinger, N. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201001080 · Cited by 36
Dinkova‐Kostova, A. T. (2012) · Scientifica · doi:10.6064/2012/606104 · Cited by 38
“�exible linker region (amino acids 210–271); (iii) middle domain (amino acids 272–628) where Hsp90 interacts with many of its client proteins; and (iv) C-terminal domain (amino acids 629–732) through which the protein dimerizes (Figure 4) [167, 168].”
BackgroundLinarès, A., Dalenc, F., Balaguer, P., Boulle, N., & Cavaillès, V. (2010) · BioMed Research International · doi:10.1155/2011/856985 · Cited by 36
“At the molecular level, one mechanism could involve the Hsp90 chaperone complex which binds to and maintains ERα in a ligand-binding conformation [107] and whose inhibition results in ubiquitin-mediated degradation of ERα by the proteasome [108].”
BackgroundHSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case–control study
Zagouri, F., Sergentanis, T. Ν., Gazouli, M., Tsigginou, A., Dimitrakakis, C., Papaspyrou, I., Eleutherakis-Papaiakovou, E., Chrysikos, D., Theodoropoulos, G. E., Zografos, G., et al. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1984-2 · Cited by 36
Lazenby, M., Hills, R. K., Burnett, A. K., & Zabkiewicz, J. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.03.016 · Cited by 36
The E3 Ligase CHIP Mediates Ubiquitination and Degradation of Mixed-Lineage Kinase 3
Blessing, N. A., Brockman, A. L., & Chadee, D. N. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00296-14 · Cited by 36
“The disruption of Hsp90 chaperone-client interactions can lead to ubiquitination and proteasomal degradation of the client proteins via Hsp70dependent recruitment of the carboxyl terminus of Hsc70-interacting protein (CHIP) E3 ubiquitin ligase (20, 22, 23).”
BackgroundErnst, K., Liebscher, M., Mathea, S., Granzhan, A., Schmid, J., Popoff, M. R., Ihmels, H., Barth, H., & Schiene‐Fischer, C. (2016) · Scientific Reports · doi:10.1038/srep20301 · Cited by 36
“On the contrary, nearly all nocodazole-treated control cells accumulated in G2/M, whereas the additionally Hsp70-inhibited cells did not accumulate in the G2/M phase but rather showed a phase distribution resembling untreated cells.”
BackgroundInfluentialLiu, F., & Fitzgerald, M. C. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00755 · Cited by 38
Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts
Ahsan, A., Ramanand, S. G., Bergin, I. L., Zhao, L., Whitehead, C. E., Rehemtulla, A., Ray, D., Pratt, W. B., Lawrence, T. S., & Nyati, M. K. (2014) · Neoplasia · doi:10.1593/neo.14182 · Cited by 38
“A number of reports published during the 1990s noted that a variety of Hsps were expressed at higher levels in various cancers than in normal tissues, probably as a stress response to conditions of hypoxia and low pH generated in tumors [34].”
BackgroundLesko, E., Goździk, J., Kijowski, J., Jenner, B., Wiecha, O., & Majka, M. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282ef532d · Cited by 39
Chemoproteomics-driven drug discovery: addressing high attrition rates
Hall, S. E. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.04.014 · Cited by 37
New Trends in Molecular Biomarker Discovery for Breast Cancer
Radpour, R., Barekati, Z., Kohler, C., Holzgreve, W., & Zhong, X. Y. (2009) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2009.0060 · Cited by 37
“The increased expression of HSPs that is observed in many tumor types has been interpreted as an effort by the malignant cells to maintain homeostasis in a hostile environment (Whitesell and Lindquist, 2005).”
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.